RxDoctor Payments Data

Joseph David, MD

Internal Medicine · Warrenton, VANPI 1851365936

Payments from drug & device makers

$10,853in general payments, 2019–2025

Across 652 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • AbbVie$1K
  • Amgen$924
  • AstraZeneca$871
  • Pfizer$653
  • plus $4K from 49 others

What the payments were for

  • Food & beverage$10,68898%
  • Education$440%
  • Other$1211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,853 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$214,189
Medicare patients
982
Services billed
3,596

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$157,676
EliquisApixaban82$74,714
FarxigaDapagliflozin Propanediol75$74,517
Trelegy ElliptaFluticasone/Umeclidin/Vilanter97$72,750
MounjaroTirzepatide47$69,600
JardianceEmpagliflozin50$52,799
TrulicityDulaglutide34$48,860
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$13,589
XareltoRivaroxaban15$10,646
LinzessLinaclotide12$9,448
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate23$6,924
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$6,365
Bevespi AerosphereGlycopyrrolate/Formoterol Fum13$5,524
Valsartan178$4,643
Breo ElliptaFluticasone/Vilanterol11$4,383

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,666$157,676107 claims
Lilly USA, LLCMounjaro, Trulicity$1,263$118,46081 claims
AstraZenecaFarxiga, Bevespi Aerosphere$871$80,04188 claims
GSKTrelegy Ellipta, Breo Ellipta$460$77,133108 claims
PfizerEliquis, Paxlovid$653$76,14496 claims
Boehringer IngelheimJardiance$306$52,79950 claims
AbbVieLinzess, Synthroid$1,210$12,51755 claims
Johnson & JohnsonXarelto$191$10,64615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Warrenton

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →